Long-term Survival of Multiple Myeloma Patients using Cure Models
Archives of Advances in Biosciences,
Vol. 15 No. 1 (2024),
24 January 2024
,
Page 1-8
https://doi.org/10.22037/aab.v15i1.43103
Abstract
Introduction: Multiple myeloma (MM) is a kind of blood cancer that is caused by the malfunction of plasma cells and their uncontrolled growth, which leads to a decrease in the level of immunity and the formation of bone lesions, especially in the spine, skull, pelvis, and ribs. Common symptoms in MM patients include severe bone pain, kidney problems, anemia, and frequent infections. This study aims to employ appropriate cure models to estimate the cure fraction and prognostic factors affecting overall survival (OS) in MM patients who have undergone transplantation.
Materials and Methods: This study has analyzed the medical records of 52 patients with multiple myeloma who were admitted to Taleghani Hospital affiliated with Shahid Beheshti University of Medical Sciences in Tehran from January 2010 to August 2016 and were followed up until February 2022. Four cure models were applied to the data and it determined the cure fraction in the Inverse Gaussian model is higher than in other models, so prognostic factors affecting the survival of patients were examined using this model.
Results: The mean age at diagnosis was 53.07 (SD =6.4). The 5-year survival rate for MM patients was 74%, and the long-term survival rate for patients in this study was 54.7%. Using the Inverse Gaussian model, the cure fraction was estimated at 54.4%
Conclusion: This study applies cure models to find prognostic factors based on pre-transplant CBC test on the survival time of MM patients who have been treated with auto-HSCT, so the number of platelets pre-transplantation and the patient's age are effective predictors for overall survival.
- Cure Fraction
- Inverse gaussian distribution
- Multiple myeloma
How to Cite
References
Li J, Zhu Y. Survival analysis of multiple myeloma patients after autologous stem cell transplantation. Stem Cell Investig. 2019;6:42. [DOI: 10.21037/sci.2019.10.05] [PMID] [PMCID]
World Corrosion Organization.2024. [Link]
American Cancer Society medical. Key Statistics for Childhood Leukemia.2023. [Link]
Global Cancer Observatory.2024. [Link]
SEER Cancer Statistics Factsheets: Leukemia. National Cancer Institute Bethesda, N.2023. [Link]
Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23(10):1691-7. [DOI: 10.1038/leu.2009.134] [PMID]
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003 Jan;78(1):21-33.[DOI:10.4065/78.1.21] [PMID]
Rajkumar SV. Updated Diagnostic Criteria and Staging System for Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2016;35:e418-23. [DOI: 10.1200/EDBK_159009] [PMID]
Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009;113(22):5412-7. [DOI:10.1182/blood-2008-12-194241] [PMID] [PMCID]
Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113(22):5418-22. [DOI: 10.1182/blood-2008-12-195008] [PMID] [PMCID]
Cleveland Clinic.Multiple Myeloma2023. [Link]
Bräutigam M, Biskup E. CME: Multiple myeloma-a review. Praxis. 2018;107(14):749-54. [DOI: 10.1024/1661-8157/a002984] [PMID]
Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E. European Myeloma
Network guidelines for the management of
multiple myeloma-related complications. Haematologica. 2015;100(10):1254-66. [DOI: 10.3324/haematol.2014.117176] [PMID] [PMCID]
Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. InMayo Clinic Proceedings 2009;84(12): 1095-1110. [DOI: 10.4065/mcp.2009.0603]
Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW,et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016;128(13):1735-44. [DOI:10.1182/blood-2016-06-723007] [PMID] [PMCID]
Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P,et al. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia. 2017;31(8):1727-1734. [DOI:10.1038/leu.2016.381] [PMID]
Dhakal B, Vesole DH, Hari PN. Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplant. 2016;51(4):492-500. [DOI:10.1038/bmt.2015.325] [PMID]
Bertrand A, Legrand C, Léonard D, Van Keilegom I. Robustness of estimation methods in a survival cure model with mismeasured covariates. Computational Statistics & Data Analysis. 2017;113:3-18. [DOI:10.1016/j.csda.2016.11.013]
MohammadSharifi A, Hajizadeh E, baghestani A, Haji Fathali A. Mixture And Non-Mixture Cured Models In Survival Analysis Of Leukemia Patients: A Cohort Study. Studies in Medical Sciences. 2020; 31 (10) :802-812. [Link]
Arano I, Sugimoto T, Hamasaki T, Ohno Y. Practical application of cure mixture model for long-term censored survivor data from a withdrawal clinical trial of patients with major depressive disorder. BMC medical research methodology. 2010;10(1):1-3. [DOI:10.1186/1471-2288-10-33]
Berkson J, Gage RP. Survival curve for cancer patients following treatment. Journal of the American Statistical Association. 1952 ;47(259): 501-15. [DOI: 10.1080/01621459.1952.10501187]
Chen MH, Ibrahim JG, Sinha D. A new Bayesian model for survival data with a surviving fraction. Journal of the American Statistical Association. 1999;94(447):909-19. [DOI: 10.1080/01621459.1999.10474196 ]
Balka J, Desmond AF, McNicholas PD. Bayesian and likelihood inference for cure rates based on defective inverse Gaussian regression models. Journal of Applied Statistics. 2011;38(1):127-44. [DOI: 10.1080/02664760903301127]
Li J, Zhu Y. Survival analysis of multiple myeloma patients after autologous stem cell transplantation. Stem Cell Investigation. 2019;6. [DOI:10.21037/sci.2019.10.05] [PMID] [PMCID]
Rajkumar SV. Treatment of multiple myeloma. Nature reviews Clinical oncology. 2011;8(8):479-91. [DOI: 10.1038/nrclinonc.2011.63]
Balka J, Desmond AF, McNicholas PD. Review and implementation of cure models based on first hitting times for Wiener processes. Lifetime data analysis. 2009;15:147-76. [DOI:10.1007/s10985-008-9108-y]
Lee ML, Whitmore GA. Threshold regression for survival analysis: modeling event times by a stochastic process reaching a boundary.2006. [DOI: 10.1214/088342306000000330]
Gieser PW, Chang MN, Rao PV, Shuster JJ, Pullen J. Modelling cure rates using the Gompertz model with covariate information. Statistics in medicine. 1998;17(8):831-9. [DOI:10.1002/(SICI)1097-0258]
Cantor AB, Shuster JJ. Parametric versus non‐parametric methods for estimating cure rates based on censored survival data. Statistics in Medicine. 1992;11(7):931-7. [DOI: 10.1002/sim.4780110710]
Cordeiro GM, de Castro M. A new family of generalized distributions. Journal of statistical computation and simulation. 2011;81(7):883-98. [DOI: 10.1080/00949650903530745]
Rocha R, Nadarajah S, Tomazella V, Louzada F, Eudes A. New defective models based on the Kumaraswamy family of distributions with application to cancer data sets. Statistical methods in medical research. 2017;26(4):1737-55. [DOI:10.1177/0962280215587976]
Team RC. R: A Language and environment for statistical Vienna, Austria; 2022. [Link]
computing. Vienna, Austria; 2022.Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D,et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98(6):980-7. [DOI: 10.3324/haematol.2012.075051] [PMID] [PMCID]
Derman BA, Langerman SS, Maric M, Jakubowiak A, Zhang W, Chiu BC. Sex differences in outcomes in multiple myeloma. British journal of haematology. 2021;192(3):e66. [DOI:10.1111/bjh.17237] [PMID] [PMCID]
Othus M, Barlogie B, Leblanc ML, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res. 2012;18(14):3731-6. [DOI:10.1158/1078-0432.CCR-11-2859] [PMID] [PMCID]
Othus M, Barlogie B, LeBlanc ML, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. Clinical Cancer Research. 2012;18(14):3731-6. [DOI:10.1158/1078-0432.CCR-11-2859]
Rocha RF. Defective models for cure rate modeling.2016. [Link]
Roshandel E, Kaviani S, Hajifathali A, Soleimani M. Pre-transplant thrombocytopenia predicts engraftment time and blood products requirement in allogeneic hematopoietic stem cell transplantation patients. Transfusion and Apheresis Science. 2020;59(4):102810. [DOI:10.1016/j.transci.2020.102810]
Wildes TM, Rosko A, Tuchman SA. Multiple myeloma in the older adult: better prospects, more challenges. Journal of clinical oncology. 2014;32(24):2531. [DOI: 10.1200/JCO.2014.55.1028] [PMID] [PMCID]
Chretien ML, Hebraud B, Cances-Lauwers V, Hulin C, Marit G, Leleu X, Karlin L,et al. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. Haematologica. 2014;99(7):1236-8. [DOI: 10.3324/haematol.2013.098608] [PMID] [PMCID]
Bird S, Cairns D, Menzies T, Boyd K, Davies F, Cook G, et al. Sex differences in multiple myeloma biology but not clinical outcomes: results from 3894 patients in the myeloma XI trial. Clin Lymphoma Myeloma Leuk. 2021;21(10):667-75. [DOI: 10.1016/j.clml.2021.04.013] [PMID] [PMCID]
- Abstract Viewed: 132 times
- pdf Downloaded: 51 times